Literature DB >> 26468275

Transthyretin Binding Heterogeneity and Anti-amyloidogenic Activity of Natural Polyphenols and Their Metabolites.

Paola Florio1, Claudia Folli2, Michele Cianci3, Daniele Del Rio2, Giuseppe Zanotti4, Rodolfo Berni5.   

Abstract

Transthyretin (TTR) is an amyloidogenic protein, the amyloidogenic potential of which is enhanced by a number of specific point mutations. The ability to inhibit TTR fibrillogenesis is known for several classes of compounds, including natural polyphenols, which protect the native state of TTR by specifically interacting with its thyroxine binding sites. Comparative analyses of the interaction and of the ability to protect the TTR native state for polyphenols, both stilbenoids and flavonoids, and some of their main metabolites have been carried out. A main finding of this investigation was the highly preferential binding of resveratrol and thyroxine, both characterized by negative binding cooperativity, to distinct sites in TTR, consistent with the data of x-ray analysis of TTR in complex with both ligands. Although revealing the ability of the two thyroxine binding sites of TTR to discriminate between different ligands, this feature has allowed us to evaluate the interactions of polyphenols with both resveratrol and thyroxine preferential binding sites, by using resveratrol and radiolabeled T4 as probes. Among flavonoids, genistein and apigenin were able to effectively displace resveratrol from its preferential binding site, whereas genistein also showed the ability to interact, albeit weakly, with the preferential thyroxine binding site. Several glucuronidated polyphenol metabolites did not exhibit significant competition for resveratrol and thyroxine preferential binding sites and lacked the ability to stabilize TTR. However, resveratrol-3-O-sulfate was able to significantly protect the protein native state. A rationale for the in vitro properties found for polyphenol metabolites was provided by x-ray analysis of their complexes with TTR.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  amyloid; fibril; fibrillogenesis; inhibitor; ligand-binding protein; negative cooperativity; polyphenol; polyphenol metabolites; transthyretin

Mesh:

Substances:

Year:  2015        PMID: 26468275      PMCID: PMC4705982          DOI: 10.1074/jbc.M115.690172

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes.

Authors:  Alexander W Schüttelkopf; Daan M F van Aalten
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-07-21

Review 2.  Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses.

Authors:  Steven M Johnson; R Luke Wiseman; Yoshiki Sekijima; Nora S Green; Sara L Adamski-Werner; Jeffery W Kelly
Journal:  Acc Chem Res       Date:  2005-12       Impact factor: 22.384

3.  Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein.

Authors:  H L Monaco; M Rizzi; A Coda
Journal:  Science       Date:  1995-05-19       Impact factor: 47.728

4.  The effect of curcumin on human islet amyloid polypeptide misfolding and toxicity.

Authors:  Marie Daval; Sahar Bedrood; Tatyana Gurlo; Chang-Jiang Huang; Safia Costes; Peter C Butler; Ralf Langen
Journal:  Amyloid       Date:  2010-11-10       Impact factor: 7.141

5.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

Review 6.  Natural compounds may open new routes to treatment of amyloid diseases.

Authors:  Jan Bieschke
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

7.  D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis?

Authors:  Per Hammarström; Yoshiki Sekijima; Joleen T White; R Luke Wiseman; Amareth Lim; Catherine E Costello; Klaus Altland; Ferenc Garzuly; Herbert Budka; Jeffery W Kelly
Journal:  Biochemistry       Date:  2003-06-10       Impact factor: 3.162

Review 8.  An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis.

Authors:  Laura Obici; Giampaolo Merlini
Journal:  Expert Opin Investig Drugs       Date:  2014-07-08       Impact factor: 6.206

9.  Structures of human transthyretin complexed with thyroxine at 2.0 A resolution and 3',5'-dinitro-N-acetyl-L-thyronine at 2.2 A resolution.

Authors:  A Wojtczak; V Cody; J R Luft; W Pangborn
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1996-07-01

Review 10.  Scaling and assessment of data quality.

Authors:  Philip Evans
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2005-12-14
View more
  13 in total

Review 1.  Inhibition of protein misfolding and aggregation by natural phenolic compounds.

Authors:  Zohra Dhouafli; Karina Cuanalo-Contreras; El Akrem Hayouni; Charles E Mays; Claudio Soto; Ines Moreno-Gonzalez
Journal:  Cell Mol Life Sci       Date:  2018-07-20       Impact factor: 9.261

Review 2.  Resveratrol: How Much Wine Do You Have to Drink to Stay Healthy?

Authors:  Sabine Weiskirchen; Ralf Weiskirchen
Journal:  Adv Nutr       Date:  2016-07-15       Impact factor: 8.701

3.  Resveratrol administration increases Transthyretin protein levels ameliorating AD features- importance of transthyretin tetrameric stability.

Authors:  L M Santos; D Rodrigues; M Alemi; S C Silva; C A Ribeiro; I Cardoso
Journal:  Mol Med       Date:  2016-06-30       Impact factor: 6.354

Review 4.  Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism.

Authors:  Jin-Beom Si; Bokyung Kim; Jin Hae Kim
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

5.  Modifications of the 7-Hydroxyl Group of the Transthyretin Ligand Luteolin Provide Mechanistic Insights into Its Binding Properties and High Plasma Specificity.

Authors:  Lina Nilsson; Andreas Larsson; Afshan Begum; Irina Iakovleva; Marcus Carlsson; Kristoffer Brännström; A Elisabeth Sauer-Eriksson; Anders Olofsson
Journal:  PLoS One       Date:  2016-04-06       Impact factor: 3.240

6.  Structural and dynamics evidence for scaffold asymmetric flexibility of the human transthyretin tetramer.

Authors:  Giuseppe Zanotti; Francesca Vallese; Alberto Ferrari; Ilaria Menozzi; Tadeo E Saldaño; Paola Berto; Sebastian Fernandez-Alberti; Rodolfo Berni
Journal:  PLoS One       Date:  2017-12-14       Impact factor: 3.240

7.  Evaluating the effect of mutations and ligand binding on transthyretin homotetramer dynamics.

Authors:  Tadeo E Saldaño; Giuseppe Zanotti; Gustavo Parisi; Sebastian Fernandez-Alberti
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

Review 8.  Cancer Chemoprevention by Resveratrol: The p53 Tumor Suppressor Protein as a Promising Molecular Target.

Authors:  Danielly C Ferraz da Costa; Eliane Fialho; Jerson L Silva
Journal:  Molecules       Date:  2017-06-18       Impact factor: 4.411

Review 9.  Polypharmacology or Promiscuity? Structural Interactions of Resveratrol With Its Bandwagon of Targets.

Authors:  Uzma Saqib; Tanya T Kelley; Siva K Panguluri; Dongfang Liu; Rajkumar Savai; Mirza S Baig; Stephan C Schürer
Journal:  Front Pharmacol       Date:  2018-10-24       Impact factor: 5.810

10.  Resveratrol prevents p53 aggregation in vitro and in breast cancer cells.

Authors:  Danielly C Ferraz da Costa; Nathali P C Campos; Ronimara A Santos; Francisca Hildemagna Guedes-da-Silva; Mafalda Maria D C Martins-Dinis; Letícia Zanphorlin; Carlos Ramos; Luciana P Rangel; Jerson L Silva
Journal:  Oncotarget       Date:  2018-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.